Ignite Creation Date:
2024-05-06 @ 5:35 PM
Last Modification Date:
2024-10-26 @ 2:32 PM
Study NCT ID:
NCT05365178
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2023-12-29
First Post:
2022-04-26
Brief Title:
To Evaluate the Efficacy and Safety of TQB3616 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant in Previously Untreated Hormone-receptor HR-Positive Human Epidermal Growth Factor Receptor 2 HER2-Negative Advanced Breast Cancer
Sponsor:
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Organization:
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Key Dates - Follows AllAPIJSON File Order
Start Date:
2022-07-01
Start Date Type:
ACTUAL
Primary Completion Date:
2024-06
Primary Completion Date Type:
ESTIMATED
Completion Date:
2026-06
Completion Date Type:
ESTIMATED
First Submit Date:
2022-04-26
First Submit QC Date:
May 6 2022
Study First Post Date:
2022-05-09
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2023-12-28
Last Update Post Date:
2023-12-29
Last Update Post Date Type:
ACTUAL